Ilumya (Tildrakizumab-Asmn) Drug Interactions: 1 Moderate
Ilumya (Tildrakizumab-Asmn) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Ilumya. Always confirm against the full prescribing information.
100 interactions
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Tildrakizumab.
Level 2 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Aducanumab is combined with Tildrakizumab.
Level 2 evidence
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tildrakizumab.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Tildrakizumab.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Amivantamab.
Level 2 evidence
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Tildrakizumab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Ansuvimab.
Level 2 evidence
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Tildrakizumab.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Tildrakizumab.
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tildrakizumab.
Level 2 evidence
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Tildrakizumab.
Level 2 evidence
Atezolizumab
The risk or severity of adverse effects can be increased when Atezolizumab is combined with Tildrakizumab.
Ilumya (Tildrakizumab-Asmn) has 162 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Ilumya (Tildrakizumab-Asmn) has 0 major, 1 moderate, and 161 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Ilumya. Always confirm against the full prescribing information.